Cost-Containment

Biosimilars are on track to save the U.S. health care system up to $183 billion by 2025.

Holding the line on costs is a leading concern for CFOs as inflation reaches the highest level in decades.

Although there are no simple answers to these questions, wrestling with them can help employers deliver better care and value.

COVID has saddled health care organizations with all kinds of expensive new problems--many of which employers will end up paying for.

While commercial-to-Medicare price ratios have been relatively stable, the costs vary substantially across regions.

This inability to make educated choices costs employees—and their employers—millions in unnecessary costs each year.